Optimizing Treatment Sequencing of Chemotherapy for Patients with Rectal Cancer: the KIR Randomized Phase II Trial

We conducted a phase 2 randomized, open-label, multicentre trial was in five institutions between 2010 and 2017(NCT01274962). Patients diagnosed with rectal cancer underwent baseline magnetic resonance imaging (MRI) of the pelvis, computed tomography scans of the chest, abdomen and pelvis, baseline serology including carcinogenic embryonic antigen testing. All patients underwent evaluation by a multidisciplinary tumor board including at least one colorectal surgeon, medical oncologist and radiation oncologist; a second radiologist reviewed imaging at tumor board for confirmation of eligibility.

Source: Radiotherapy and Oncology - November 18, 2020 Category: Radiology Authors: Aurelie Garant, Petr Kavan, Andr é-Guy Martin, Laurent Azoulay, Véronique Vendrely, Caroline Lavoie, Carol-Ann Vasilevsky, Marylise Boutros, Julio Faria, Trung Nghia Nguyen, Emery Ferland, Sylvain Des Groseilliers, Alexis-Simon Cloutier, Hugo Diec, Séb Tags: Original Article Source Type: research